tbuckley/cabot-search huggingface dataset:
MicroRNAs as a diagnostic tool for differentiating squamous cell lung cancer from other non small cell lung cancers
Authors: D. Lebanony, H. Benjamin, S. Gilad, J. Li, H. Cholakh, N. Shabes, D. Cohen, M. Mansukhani
Journal: Journal of Clinical Oncology (2008)

22018 Background: MicroRNAs are short non-coding RNAs that regulate differentiation and development in various organisms, and have been shown to be involved as regulators of many cancer-related processes. Therefore microRNAs are potential biomarkers and novel drug targets for diagnostic and therapeutic applications. Lung cancer is the leading cause of cancer-related death among men and women. Of all lung cancer cases, 80% are non-small-cell lung cancer (NSCLC) which includes adenocarcinoma, squamous-cell carcinoma and large-cell carcinoma. Careful diagnosis of lung cancer patients before treatment with angiogenesis inhibitor drugs is critical due to life- threatening risk of pulmonary bleeding. Specifically, squamous histology is an exclusion criterion due to increased risk of fatal hemorrhage and other complications. Methods: Using proprietary protocols, we extracted RNA from more than 100 NSCLC formalin-fixed paraffin-embedded (FFPE) samples. The expression levels of ∼700 human microRNAs were determined using a proprietary microarray. Based on these results, we developed a quantitative Real-Time PCR (qRT-PCR) assay to detect squamous histology. Results: A single microRNA was found sufficient to discriminate squamous cell carcinoma from other types of NSCLC. The expression level of the discriminator microRNA normalized by two other RNAs (one microRNA and one small RNA) was determined using qRT-PCR. A near perfect separation between over 40 samples of lung squamous cell carcinoma and samples of non-squamous origin was achieved on the assay. Conclusions: We developed a highly accurate microRNA-based diagnostic assay that identifies lung squamous cell carcinoma, an important exclusion criterion in angiogenesis inhibitor treatments. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Rosetta Genomics Rosetta Genomics
A study of mood states and diurnal salivary cortisol rhythms in breast cancer patients awaiting radiotherapy: A cross sectional study
Authors: N. Raizada, H. S. Vadiraja, R. M. Raghavendra, B. S. Ajaikumar, R. S. Bilimagga, M. Rekha, N. Vanitha, N. Usha, R. Nagarathna, H. R. Nagendra
Journal: Journal of Clinical Oncology (2008)

22160 Background: Both depression and aberrant cortisol rhythms have been independently related to poor prognosis in breast cancer patients. In this study we evaluated the relationship between self report anxiety, depression, salivary cortisol levels and rhythms in breast cancer outpatients awaiting adjuvant radiotherapy. Methods: Eighty-Nine stage II and III breast cancer patients (47.4 ± 9.6 years) awaiting radiotherapy were assessed for self report anxiety and depression using Hospital Anxiety and Depression Scale. Based on the scores for anxiety and depression (cut off score 7), subjects were categorized to have no anxiety or depression, both anxiety and depression or either one of them. Saliva samples were collected at 6 am, 9 am and 9 pm using sterile salivettes for three consecutive days before starting adjuvant radiotherapy. Diurnal salivary cortisol slope patterns were determined for each subject and categorized as abnormal (inverted V, V slope, upward and flat slopes) and normal (downward slope). Results: Thirty percent of subjects had no anxiety or depression, forty six percent had both anxiety and depression and twenty four percent had either one of these. Non-parametric Kruskal Wallis test showed significant higher levels of cortisol at 6 am (p = 0.002), 9 am (p = 0.05), 9 pm (p = 0.005) and overall diurnal mean cortisol levels (p = 0.007) in subjects with both anxiety and depression than other groups. Linear regression analysis showed both anxiety and depression status to be a significant primary predictor (β = -0.41, p = 0.03) for 6 am cortisol levels and overall diurnal mean cortisol level (β = -0.37, p = 0.04) and depression status alone as a significant predictor for 9 pm cortisol levels (β = -0.46, p = 0.005). However, anxiety and depression status did not influence salivary cortisol slope patterns. Conclusions: The results suggest HPA-axes dysregulation in breast cancer patients with self reported symptoms of anxiety and depression. Further studies should evaluate the role of stress reduction interventions in modulating HPA-axes dysregulation in cancer patients with clinical diagnosis of depressive disorders. No significant financial relationships to disclose.
DIE heterogenetischen Hammelblutantikörper UND ihre Antigene.
Authors: Hans Schmidt
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Influence of Pulmonary Regurgitation Inequality on Differential Perfusion of the Lungs in Tetralogy of Fallot After Repair
Authors: Ming-Ting Wu, Yi-Luan Huang, Kai-Sheng Hsieh, Ju-Tung Huang, Nan-Jing Peng, Jun-Yen Pan, Jer-Shyung Huang, Tsung-Lung Yang
Journal: Journal of the American College of Cardiology (2007)
Abstract 2176: Prenatal Hypoxic Stress Causes Cardiomyopathy Involving Cardiomyocyte Specific Vascular Endothelial Growth Factor Signaling
Authors: Andrei Tintu, Ellen Rouwet, Shakil Ahmad, Asif Ahmed, Marc van Bilsen, Peter Carmeliet, Anne Eichmann, Erik Harks, Leo Hofstra, Wouter Lamers, Jagat Narula, Ferdinand le Noble
Journal: Circulation (2006)

introduction Cardiovascular diseases in adulthood can be programmed in utero by prenatal stresses. The mechanism is unknown but may involve hypoxia. We assessed the hypothesis that prenatal hypoxic...
Antimicrobial Agents and Chemotherapy— 1962; Proceedings of the Second Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, October 31-November 2, 1962.
Authors: J. C. Sylvester
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
Outline of Electrocardiography.
Authors: H. Harold Friedman
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tyrosine kinase inhibitor NVP-AEW541 as a new option for the treatment of biliary tract cancer?
Authors: M. W. Wiedmann, J. Lorenz, C. Möbius, J. Mössner, S. Wolf
Journal: Journal of Clinical Oncology (2008)

14622 Background: Biliary tract cancer is associated with a poor prognosis due to wide resistance to chemotherapeutic agents and radiotherapy. Insulin-like growth factor-1 receptor (IGF-1R) is a multifunctional membrane associated tyrosine kinase that is mitogenic, protects normal and tumor cells from apoptosis, and plays an important role in supporting cellular transformation by different viral and cellular oncoproteins. Pyrrolo[2,3-d]pyrimidine derivative NVP-AEW541,an inhibitor of IGF-1R,may be a novel treatment alternative for biliary tract cancer. Methods: Cell-growth inhibition by NVP-AEW541± gemcitabine or 5-FU was studied in vitro in 7 human biliary tract cancer cell lines. In addition, anti-tumoral drug mechanism was assessed by RT-PCR for IGF-1R ligand IGF-1, immunoblotting for IGF-1R, Phospho-IGF-1R, AKT, Phospho-AKT, p42/p44, Phospho-p42/p44, and cell cycle analysis. Results: In vitro treatment suppressed the growth of all cancer cell lines with a mean IC50 (3d) of 0.51 μM and a mean IC50 (6d) of 0.22 μM, respectively. IGF-1R and IGF-1 were co-expressed suggesting an autocrine loop of tumor cell activation. In addition, treatment with NVP-AEW541 was associated with dephosphorylation of Phospho-IGF-1R, Phospho-AKT, and Phospho-p42/p44. Moreover, treated cells showed cell cycle arrest at G1/S-checkpoint and an increase in apoptosis (sub-G1-peak). Finally, NVP-AEW541 showed a synergistic effect with gemcitabine, particularly in low concentrations, but only an additive effect with 5-FU. Conclusions: Our findings suggest that NVP- AEW541 is active against human biliary tract cancer in vitro. In addition, the compound potentiated the efficacy of gemcitabine. Therefore, further preclinical and clinical evaluation of this new drug for the treatment of biliary tract cancer is recommended. No significant financial relationships to disclose.
Diseases of the Skin: A Text-Book for Practitioners and Students.
Authors: George Clinton Andrews
Journal: JAMA (1931)

This new contribution to the too numerous treatises on dermatology is hard to characterize briefly and at the same time justly. It has some excellent points and some very weak ones. It is in turn voluminous and meager. It gives 74 pages to the principles of dermatology, except treatment; it seems to the reviewer that this material is inadequate and confused. The sole attention the author gives to pathology is given in this chapter. No reference is made to the pathology of the various diseases when he considers them individually, and very little to differential diagnosis. The author's general consideration of treatment is voluminous to an extraordinary degree, 200 pages being given to this subject, 130 of them to x-rays, Grenz rays, radium and ultraviolet rays. Much of this is useful; much of it is too elaborate and confusing. His consideration of the various diseases is satisfactory, as far as
The Scientific Basis of Psychiatry.
Authors: Malcolm Weller, Michael W. Eysenck
Journal: Annals of Internal Medicine (1984)

Changing frontiers historical introduction to psychiatry. Part 1 Methodology: rating scale methods - validity and reliability the rationale of clinical trials statistics in psychiatry research epidemiology. Part 2 Neurological sciences: neurophysiological aspects of psychiatry neuropsychology and the localization of cognitive function the synapse, receptors and Alzheimer's Disease some aspects of the use of EEG in psychiatry some issues in clinical neurology. Part 3 Genetics: the principles of genetics as applied to psychiatry the genetics of major psychiatric syndromes. Part 4 Psychology: psychology or psychiatry - an information-processing account perception and attention sleep and activation principles of learning human memory intelligence emotion and stress some biological, psychological and social factors in development personality. Part 5 Social processes: the development of the psychotherapies - a brief historical overview the family and social origins of anti-social behaviour ethology group process and non-verbal communications transcultural psychiatry life events. Part 6 Clinical psychopharmacology and electroconvulsive therapy: anxiolytic and hypnotic drugs depressive illness and antidepressant drugs neurotransmitters and schizophrenia neuroleptics electroconvulsive therapy.
Low Back Pain
Authors: Roger Chou
Journal: Annals of Internal Medicine (2014)

Letters18 November 2014Low Back PainRoger Chou, MDRoger Chou, MDFrom Oregon Health & Science University, Portland, Oregon.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L14-5024-2 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Estimates for the prevalence of ankylosing spondylitis in patients with low back pain vary depending on the population studied and the criteria used to define this condition. The approximate prevalence of 0.3% is based on estimates from patients in the primary care setting with low back pain and unequivocal radiologic changes (1). The prevalence may be as high as 5% when using wider diagnostic criteria for axial spondyloarthritis (2), but the clinical manifestations and severity of symptoms vary substantially for this group of conditions.Although risk assessment instruments may be useful to identify persons at higher risk for ...References1. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268:760-5. [PMID: 1386391] CrossrefMedlineGoogle Scholar2. Underwood MR, Dawes P. Inflammatory back pain in primary care. Br J Rheumatol. 1995;34:1074-7. [PMID: 8542211] CrossrefMedlineGoogle Scholar3. Weisman MH, Chen L, Clegg DO, Davis JC, Dubois RW, Prete PE, et al. Development and validation of a case ascertainment tool for ankylosing spondylitis. Arthritis Care Res (Hoboken). 2010;62:19-27. [PMID: 20191487] doi:10.1002/acr.20009 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Oregon Health & Science University, Portland, Oregon.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L14-0377. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoLow Back Pain Roger Chou Metrics Cited byManual Lifting Standards: Ergonomic Assessment and Proposals for Redesign for Industrial Applications 18 November 2014Volume 161, Issue 10Page: 762KeywordsAlgorithmsAnkylosing spondylitisDisclosureLikelihood ratioLower back painMedical risk factorsPositive predictive valueRisk assessmentsSpecificity ePublished: 18 November 2014 Issue Published: 18 November 2014 Copyright & PermissionsCopyright © 2014 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Enzastaurin safety review: Data from phase I and phase II trials
Authors: V. Watkins, S. Hong, B. Lin
Journal: Journal of Clinical Oncology (2006)

13077 Background: Enzastaurin, an oral inhibitor of PKC and PI3K/AKT pathways, blocks tumor angiogenesis, tumor cell proliferation and induces tumor cell death. Enzastaurin has demonstrated promise in phase I and II trials in patients (pts) with various advanced cancers. We report preliminary analysis of safety data of enzastaurin, obtained in previous trials, with particular consideration to long-term therapy. Methods: Data available to date from 3 different non-randomized, single-arm trials in pts with advanced cancers, diffuse large B cell lymphoma and mantle cell lymphoma, were analyzed with regards to treatment emergent adverse events (TEAEs). Severities were defined by NCI guidelines and investigators assessed the relatedness of AEs to enzastaurin. Results: A total of 135 pts (58 F; 77 M), mean age 64 years (range: 24–87) received 20–700 mg oral enzastaurin daily (103 pts at 525 mg). 36 pts were dosed for 0–30 days, 45 for 31–60 days, 35 for 61–180 days and 19 for ≥ 180 days. No deaths were related to enzastaurin. Chromaturia was the most common drug-related event (14%). No drug-related bone marrow suppression, Gr 3 neutropenia, thrombocytopenia or anemia was reported. TEAEs in ≥ 15% pts, or drug-related events ≥ Gr 3 reported in &gt; 1 pt, are listed in the table . Other Gr 3 AEs, including edema, migraine and peripheral motor neuropathy were observed in 1 pt, each. Pts on therapy for ≤ 30 D reported highest number of AEs, consistent with the severity of their disease. Pts with exposure ≥ 180 days did not experience any drug related AE ≥ Gr 3. Conclusions: Enzastaurin is well tolerated across all doses and for extended durations with minimal AEs. In the 19 patients who received oral enzastaurin for ≥ 180 days, there was no indication of increased severity of any event. Given the severity of the disease and the absence of controlled studies for comparison, no event other than chromaturia or fecal discoloration (due to reddish-orange color of the active ingredient) appears to be definitively attributable to enzastaurin by this analysis. [Table: see text] [Table: see text]
A brief symptom index for renal cell carcinoma
Authors: D. T. Eton, D. Cella, J. Bacik, R. J. Motzer
Journal: Journal of Clinical Oncology (2006)

4595 Background: Renal cell carcinoma (RCC) occurs in over 30,000 Americans each year. Since it is often diagnosed in later stages and metastatic sites are variable, an array of symptoms and concerns affect patients with this disease. Our objective was to test a brief, symptom index for advanced RCC. Methods: We conducted secondary data analyses on patient-reported outcomes from a completed Phase III trial of 284 patients with metastatic RCC treated with interferon + 13-cis-retinoic acid or interferon alone (Motzer et al., 2000). Patient-reported outcomes were collected using the FACT-Biological Response Modifier (FACT-BRM) module at baseline, 2 weeks, and 8 weeks. We analyzed data from eight FACT-BRM items that were previously identified by clinical experts to represent the most important symptoms of advanced RCC. Items comprising the proposed Kidney Cancer Symptom Index (KCSI) assess nausea, pain, appetite, perceived sickness, fatigue and weakness, with higher KCSI scores indicating fewer symptoms. We determined the reliability and concurrent validity of the KCSI and estimated a minimally important difference (MID). Results: The KCSI had excellent internal reliability at all three time points (alphas = 0.85). Baseline KCSI scores were able to discriminate patients across Karnofsky performance status (KPS 80–90 &gt; KPS 70; F (2, 210) = 15.5, p &lt; .001), number of identified metastatic sites (0–1 site &gt; 2+ sites; t (211) = 3.2, p &lt; .01), and risk group categories (favorable or intermediate risk &gt; poor risk; F (2, 205) = 9.9, p &lt; .001). No differences were observed in KCSI change scores over time across two objective clinical indicators: response to treatment and time to progression. All patients evidenced declines in scores from baseline likely indicative of the toxic nature of the treatments. Distribution- and anchor-based methods converged on an MID estimate of 2 to 3 points for the KCSI. Conclusions: The 8-item KCSI appears to be a psychometrically sound measure of patient-reported symptoms of RCC. It is a brief, reliable, and valid measure that can easily be adapted for use in clinical trials and observational studies. [Table: see text]
Irving J, Matheson E, Minto L, et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood. 2014;124(23):3420-3430.
Authors: J Irving, E Matheson, L Minto, H Blair, M Case, C Halsey, I Swidenbank, F Ponthan, R Kirschner-Schwabe, S Groeneveld-Krentz, J Hof, J Allan, C Harrison, J Vormoor, von, Stackelberg, A, C Eckert
Journal: Blood (2015)
Applied Pathology in Diseases of the Nose, Throat, and Ear.
Authors: Joseph Carl Beck
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal